Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631415 | 1.00 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12384333 | 0.84 | GRIA1 (0.48) | GRIA1PTPN1PSEN1PSEN2APH1B | |
| SCHEMBL2631406 | 0.84 | GRIA1 (0.48) | GRIA1PTPN1PSEN1PSEN2APH1B | |
| SCHEMBL2101102 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL2628415 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL13408044 | 0.78 | HDAC6 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2102601 | 0.77 | MLYCD (0.40) | PTPN1 | |
| SCHEMBL21881743 | 0.75 | FOLH1 (0.50) | GRIA1PTPN1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL888243 | 0.74 | MEN1 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2100045 | 0.74 | MEN1 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440988-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2016-09-13 | — | — | US | disclosed |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | BEACHY PHILIP A (US) | 2012-05-31 | — | — | US | disclosed |
| US-8163719-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110263519-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-10-27 | — | — | US | disclosed |
| US-7998946-B2 | Veratrum-type alkaloid inhibits mitotic cell proliferation in hedgehog-mediated signal transduction with an ED50 of 1 mM or less; preparations administered systemically, locally, topically; cancer; non-malignant hyperproliferative disorders | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998946-B2 | Veratrum-type alkaloid inhibits mitotic cell proliferation in hedgehog-mediated signal transduction with an ED50 of 1 mM or less; preparations administered systemically, locally, topically; cancer; non-malignant hyperproliferative disorders | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-08-16 | — | — | US | disclosed |
| US-7476661-B2 | Regulators of the hedgehog pathway, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080255059-A1 | Regulators of the hedgehog pathway, compositions and uses related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255059-A1 | Regulators of the hedgehog pathway, compositions and uses related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255059-A1 | Regulators of the hedgehog pathway, compositions and uses related thereto | SHH, GLI1, SMO | HDAC3 965/4885HDAC4 1621/4885HDAC1 997/4885 |
| US-20120135066-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | HDAC3 965/4885HDAC4 1621/4885HDAC1 997/4885 |
| US-20110263519-A1 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | HDAC3 965/4885HDAC4 1621/4885HDAC1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.